
  
    
      
        Introduction_NNP
        IL-_NNP 1_CD has_VBZ been_VBN implicated_VBN as_IN a_DT pathogenic_JJ mediator_NN in_IN
        numerous_JJ inflammatory_JJ and_CC degenerative_JJ conditions_NNS ,_,
        including_VBG rheumatoid_NN arthritis_NN (_( RA_NNP )_) and_CC osteoarthritis_NNS (_( OA_NNP )_)
        [_NN 1_CD ]_NN ._. The_DT IL-_NNP 1_CD receptor_NN antagonist_NN (_( IL-_NNP 1_CD Ra_NNP )_) ,_, a_DT naturally_RB
        occurring_VBG inhibitor_NN of_IN the_DT biologic_JJ actions_NNS of_IN IL-_NNP 1_CD ,_, has_VBZ
        obvious_JJ therapeutic_JJ potential_NN in_IN such_JJ diseases_NNS [_NN 2_CD ]_NN ;_:
        indeed_RB recombinant_JJ human_JJ IL-_NNP 1_CD Ra_NNP (_( anakinra_NN )_) has_VBZ recently_RB
        been_VBN approved_VBN for_IN use_NN in_IN patients_NNS with_IN RA_NNP as_IN the_DT drug_NN
        Kineret_NNP ™_NN (_( Amgen_NNP ,_, Inc_NNP ._. ,_, Thousand_NNP Oaks_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
        Limitations_NNPS of_IN IL-_NNP 1_CD Ra_NNP as_IN a_DT pharmaceutical_JJ include_VBP its_PRP$
        lack_NN of_IN oral_JJ availability_NN and_CC its_PRP$ short_JJ biologic_JJ half-life_NN ._.
        This_DT is_VBZ why_WRB in_IN clinical_JJ application_NN Kineret_NNP ™_NN must_MD be_VB
        administered_VBN by_IN daily_JJ subcutaneous_JJ injection_NN ._. Even_RB then_RB ,_, it_PRP
        remains_VBZ unlikely_JJ that_IN a_DT therapeutic_JJ concentration_NN of_IN IL-_NNP 1_CD Ra_NNP
        will_MD be_VB maintained_VBN between_IN injections_NNS [_NN 3_CD ]_NN ;_: IL-_NNP 1_CD Ra_NNP is_VBZ
        rapidly_RB eliminated_VBN in_IN the_DT kidney_NN ,_, resulting_VBG in_IN a_DT serum_NN
        half-life_NN of_IN 4_CD -_: 6_CD hours_NNS following_VBG intravenous_JJ injection_NN into_IN
        healthy_JJ ,_, human_JJ volunteers_NNS ._. This_DT problem_NN is_VBZ exacerbated_VBN by_IN
        the_DT pronounced_VBN spare_JJ receptor_NN effect_NN of_IN IL-_NNP 1_CD ._. According_VBG to_TO
        the_DT literature_NN [_NN 4_CD 5_CD 6_CD ]_NN it_PRP is_VBZ necessary_JJ to_TO maintain_VB an_DT
        IL-_NNP 1_CD Ra_NNP :_: IL-_NNP 1_CD molar_NN ratio_NN of_IN 10_CD -_: 100_CD or_CC more_JJR to_TO achieve_VB a_DT
        strong_JJ inhibitory_NN effect_NN ._.
        We_PRP have_VBP proposed_VBN IL-_NNP 1_CD Ra_NNP gene_NN transfer_NN as_IN a_DT means_NN of_IN
        overcoming_VBG these_DT problems_NNS [_NN 7_CD ]_NN ._. The_DT advantages_NNS of_IN IL-_NNP 1_CD Ra_NNP
        gene_NN delivery_NN include_VBP its_PRP$ ability_NN to_TO engender_NN the_DT
        continuous_JJ production_NN of_IN therapeutic_JJ concentrations_NNS of_IN
        IL-_NNP 1_CD Ra_NNP at_IN defined_VBN anatomic_JJ locations_NNS for_IN extended_VBN periods_NNS
        of_IN time_NN -_: potentially_RB for_IN life_NN ._. Moreover_RB ,_, it_PRP is_VBZ
        theoretically_RB possible_JJ to_TO regulate_VB levels_NNS of_IN IL-_NNP 1_CD Ra_NNP gene_NN
        expression_NN in_IN a_DT manner_NN commensurate_JJ with_IN disease_NN activity_NN [_NN
        8_CD ]_NN ._. IL-_NNP 1_CD Ra_NNP gene_NN therapy_NN has_VBZ been_VBN evaluated_VBN in_IN a_DT number_NN of_IN
        different_JJ animal_NN models_NNS of_IN RA_NNP and_CC OA_NNP ,_, with_IN extremely_RB
        promising_JJ results_NNS [_NN 9_CD 10_CD 11_CD 12_CD 13_CD 14_CD 15_CD 16_CD 17_CD 18_CD ]_NN ._.
        Indeed_RB ,_, a_DT phase_NN I_PRP human_JJ study_NN of_IN IL-_NNP 1_CD Ra_NNP gene_NN therapy_NN in_IN RA_NNP
        [_NN 19_CD ]_NN was_VBD recently_RB successfully_RB completed_VBN ._.
        During_IN the_DT preclinical_JJ development_NN of_IN IL-_NNP 1_CD Ra_NNP gene_NN
        therapy_NN ,_, we_PRP often_RB noticed_VBD that_WDT transfer_NN of_IN the_DT IL-_NNP 1_CD Ra_NNP gene_NN
        provided_VBD a_DT far_RB greater_JJR biologic_JJ effect_NN than_IN administration_NN
        of_IN the_DT recombinant_JJ protein_NN ._. An_DT example_NN is_VBZ provided_VBN by_IN the_DT
        treatment_NN of_IN antigen-induced_JJ arthritis_NN in_IN rabbits_NNS ._.
        Lewthwaite_NNP and_CC coworkers_NNS [_NN 20_CD ]_NN reported_VBD that_WDT repeated_VBD
        injection_NN of_IN recombinant_JJ human_JJ IL-_NNP 1_CD Ra_NNP had_VBD no_DT effect_NN in_IN this_DT
        model_NN of_IN RA_NNP beyond_IN inhibition_NN of_IN the_DT synovial_NN fibrosis_NNS
        occurring_VBG in_IN the_DT chronic_JJ stage_NN of_IN the_DT disease_NN ._. Otani_NNP and_CC
        colleagues_NNS [_NN 16_CD ]_NN ,_, in_IN contrast_NN ,_, observed_VBD a_DT dramatic_JJ
        beneficial_JJ effect_NN on_IN cartilage_NN matrix_NN metabolism_NN ,_, and_CC a_DT
        moderate_JJ anti-inflammatory_JJ effect_NN when_WRB administering_VBG IL-_NNP 1_CD Ra_NNP
        locally_RB to_TO joints_NNS via_IN 
        ex_FW vivo_NN gene_NN transfer_NN ._.
        There_EX exist_VB several_JJ possible_JJ explanations_NNS for_IN the_DT
        improved_VBN effectiveness_NN of_IN IL-_NNP 1_CD Ra_NNP when_WRB delivered_VBN as_IN a_DT gene_NN
        rather_RB than_IN as_IN a_DT recombinant_JJ protein_NN ._. The_DT most_RBS likely_JJ of_IN
        these_DT are_VBP as_IN follows_VBZ ._. First_LS ,_, gene_NN transfer_NN results_NNS in_IN
        continuous_JJ ,_, rather_RB than_IN intermittent_JJ ,_, protein_NN delivery_NN ,_,
        thus_RB maintaining_VBG a_DT constant_JJ supply_NN of_IN IL-_NNP 1_CD Ra_NNP at_IN a_DT
        concentration_NN sufficient_JJ to_TO inhibit_VB the_DT biologic_JJ actions_NNS of_IN
        IL-_NNP 1_CD ._. Second_JJ ,_, gene_NN delivery_NN produces_VBZ a_DT molecule_NN that_WDT has_VBZ
        been_VBN subjected_VBN to_TO authentic_JJ post-translational_JJ processing_NN ._.
        Because_IN the_DT recombinant_JJ molecule_NN lacks_VBZ glycosylation_NN and_CC
        has_VBZ an_DT extra_JJ amino-terminal_JJ methionine_NN ,_, the_DT native_JJ molecule_NN
        may_MD have_VB greater_JJR biologic_JJ potency_NN than_IN the_DT recombinant_JJ
        one_CD ._.
        The_DT present_JJ study_NN was_VBD designed_VBN to_TO compare_VB quantitatively_RB
        the_DT relative_JJ effectiveness_NN of_IN these_DT two_CD avenues_NNS of_IN protein_NN
        delivery_NN under_IN controlled_VBN conditions_NNS 
        in_IN vitro_NN ._. Cultures_NNP of_IN primary_JJ human_JJ
        synovial_NN fibroblasts_NNS (_( HSFs_NNP )_) were_VBD treated_VBN with_IN human_JJ IL-_NNP 1_CD Ra_NNP ,_,
        either_CC administered_VBN as_IN the_DT recombinant_JJ protein_NN or_CC by_IN
        co-culture_JJ with_IN fibroblasts_NNS genetically_RB engineered_VBN to_TO
        express_VB and_CC secrete_NN human_JJ IL-_NNP 1_CD Ra_NNP in_IN a_DT constitutive_JJ manner_NN ._.
        Stimulation_NNP from_IN human_JJ IL-_NNP 1_CD β_NN was_VBD then_RB provided_VBN by_IN addition_NN
        of_IN recombinant_JJ IL-_NNP 1_CD β_NN protein_NN or_CC by_IN co-culture_JJ with_IN
        fibroblasts_NNS genetically_RB engineered_VBN to_TO constitutively_RB
        secrete_NN high_JJ levels_NNS of_IN human_JJ IL-_NNP 1_CD β_NN [_NN 21_CD ]_NN ._. Using_VBG
        prostaglandin_NN E_NNP 
        2_CD (_( PGE_NNP 
        2_LS )_) levels_NNS in_IN conditioned_VBN media_NNS as_IN a_DT
        readout_NN of_IN IL-_NNP 1_CD stimulation_NN in_IN the_DT respective_JJ cultures_NNS ,_,
        protection_NN from_IN IL-_NNP 1_CD stimulation_NN by_IN each_DT method_NN was_VBD
        evaluated_VBN under_IN static_JJ and_CC dynamic_JJ culture_NN conditions_NNS ,_, the_DT
        latter_NN of_IN which_WDT were_VBD designed_VBN to_TO resemble_VB more_RBR closely_RB the_DT
        circumstance_NN of_IN an_DT arthritic_JJ joint_NN in_IN which_WDT IL-_NNP 1_CD is_VBZ
        chronically_RB produced_VBN ._.
        The_DT data_NNS suggest_VBP that_IN the_DT recombinant_JJ and_CC transgenic_JJ
        molecules_NNS are_VBP similarly_RB potent_JJ ._. Although_IN the_DT gene_NN delivery_NN
        procedure_NN may_MD benefit_VB marginally_RB from_IN increased_VBN
        concentration_NN at_IN the_DT cellular_JJ level_NN ,_, the_DT advantage_NN of_IN gene_NN
        transfer_NN as_IN a_DT means_NN of_IN drug_NN delivery_NN arises_VBZ from_IN the_DT
        sustained_VBN availability_NN of_IN IL-_NNP 1_CD Ra_NNP that_IN this_DT method_NN
        permits_NNS ._.
      
      
        Materials_NNS and_CC method_NN
        
          Materials_NNS
          Ham_NNP 's_POS F_NN 12_CD medium_NN ,_, Dulbecco_NNP 's_POS modified_VBN Eagle_NNP medium_NN
          (_( DMEM_NNP )_) ,_, fetal_JJ bovine_JJ serum_NN (_( FBS_NNP )_) ,_,
          penicillin-streptomycin_JJ ,_, type_NN II_NNP collagenase_NN ,_, dispase_NN ,_,
          and_CC Geneticin_NNP ™_NN were_VBD supplied_VBN by_IN Gibco-_NNP BRL_NNP (_( Rockville_NNP ,_, MD_NNP ,_,
          USA_NNP )_) ._. Zeocin_NNP ™_NN was_VBD obtained_VBN from_IN Invitrogen_NNP (_( Carlsbad_NNP ,_, Ca_NNP ,_,
          USA_NNP )_) ._. Recombinant_NNP human_JJ IL-_NNP 1_CD β_NN and_CC IL-_NNP 1_CD Ra_NNP were_VBD purchased_VBN
          from_IN R_NN &_CC D_NNP Systems_NNPS (_( Minneapolis_NNP ,_, MN_NNP ,_, USA_NNP )_) ._. ELISA_NNP kits_NNS
          for_IN PGE_NNP 
          2_CD and_CC IL-_NNP 1_CD Ra_NNP were_VBD purchased_VBN from_IN
          Dynatech_NNP (_( Ann_NNP Arbor_NNP ,_, MI_NNP ,_, USA_NNP )_) and_CC R_NN &_CC D_NNP Systems_NNPS ,_,
          respectively_RB ._. ELISA_NNP kits_NNS for_IN human_JJ IL-_NNP 1_CD β_NN were_VBD purchased_VBN
          from_IN Endogen_NNP (_( Woburn_NNP ,_, MA_NNP ,_, USA_NNP )_) ._.
        
        
          Reporter_NNP cell_NN cultures_NNS
          Human_JJ synovial_NN tissues_NNS were_VBD recovered_VBN from_IN joints_NNS of_IN
          OA_NNP patients_NNS undergoing_VBG total_JJ joint_JJ replacement_NN surgery_NN ._.
          HSFs_NNP were_VBD isolated_VBN by_IN sequential_NN digestion_NN of_IN synovial_NN
          fragments_NNS with_IN 1_CD ._. 5_CD %_NN dispase_NN for_IN 2_CD hours_NNS at_IN 37_CD °_NN C_NNP and_CC 0_CD ._. 2_CD %_NN
          collagenase_NN for_IN 2_CD hours_NNS ._. After_IN washing_VBG in_IN
          phosphate-buffered_JJ saline_NN the_DT cells_NNS were_VBD cultured_JJ in_IN 25_CD
          cm_NN 2_CD dishes_NNS in_IN DMEM_NNP with_IN 10_CD %_NN FBS_NNP and_CC 1_CD %_NN
          penicillin-streptomycin_JJ ._. After_IN the_DT third_JJ passage_NN ,_, the_DT
          type_NN B_NNP synovial_NN cells_NNS were_VBD trypsinized_JJ ,_, counted_VBN ,_, and_CC
          cultured_JJ at_IN a_DT density_NN of_IN 5_CD ×_NN 10_CD 5_CD cells_NNS per_IN well_RB in_IN
          24_CD -_: well_RB plates_NNS with_IN 1_CD ml_NN DMEM_NNP supplemented_JJ with_IN 10_CD %_NN FBS_NNP
          and_CC 1_CD %_NN penicillin-streptomycin_JJ ._.
        
        
          Engineered_NNP cell_NN lines_NNS
          To_TO generate_VB a_DT cell_NN line_NN that_WDT provided_VBD a_DT source_NN of_IN
          constitutive_JJ production_NN and_CC secretion_NN of_IN transgenic_JJ
          IL-_NNP 1_CD Ra_NNP ,_, the_DT rabbit_NN synovial_NN cell_NN line_NN HIG-_NNP 82_CD [_NN 22_CD ]_NN was_VBD
          cultured_JJ in_IN 25_CD cm_NN 2_CD flasks_NNS containing_VBG 4_CD ml_NN Ham_NNP 's_POS F_NN 12_CD
          medium_NN with_IN 10_CD %_NN FBS_NNP and_CC 1_CD %_NN penicillin-streptomycin_JJ ._. Cells_NNP
          were_VBD grown_VBN to_TO approximately_RB 75_CD %_NN confluence_NN and_CC incubated_JJ
          in_IN the_DT presence_NN of_IN 8_CD μg_NN /_NN ml_NN polybrene_NN with_IN 2_CD ml_NN
          supernatant_NN containing_VBG amphotropic_JJ retrovirus_JJ
          DFG-IRAP-zeo_NNP rcontaining_VBG the_DT human_JJ IL-_NNP 1_CD Ra_NNP and_CC 
          Streptoalloteichus_NNP
          hindustanus_JJ bleomycin-resistance_JJ (_( 
          Sh_NNP ble_JJ ;_: zeo_NN r_LS )_) genes_NNS ._. The_DT latter_JJ
          allowed_VBN positive_JJ selection_NN of_IN the_DT transduced_JJ cells_NNS in_IN
          medium_NN containing_VBG Zeocin_NNP at_IN 0_CD ._. 5_CD mg_NN /_NN ml_NN ._. These_DT cells_NNS ,_,
          HIG-_NNP 82_CD -_: IL-_NNP 1_CD Ra_NNP +_NN ,_, were_VBD found_VBN to_TO secrete_NN approximately_RB 3_CD μg_NN
          IL-_NNP 1_CD Ra_NNP /_NN ml_NN per_IN 10_CD 6_CD cells_NNS over_IN 24_CD hours_NNS ._. The_DT HIG-_NNP 82_CD cells_NNS
          were_VBD chosen_VBN for_IN this_DT purpose_NN because_IN they_PRP do_VBP not_RB produce_VB
          PGE_NNP 
          2_CD in_IN response_NN to_TO IL-_NNP 1_CD β_NN ._. Non-transduced_NNP
          HIG-_NNP 82_CD cells_NNS used_VBN as_IN negative_JJ controls_NNS were_VBD cultured_JJ in_IN
          Ham_NNP 's_POS F_NN 12_CD medium_NN with_IN 10_CD %_NN FBS_NNP and_CC 1_CD %_NN
          penicillin-streptomycin_JJ ._.
          To_TO generate_VB cells_NNS that_WDT constitutively_RB expressed_VBD human_JJ
          IL-_NNP 1_CD β_NN ,_, skin_NN was_VBD first_RB harvested_VBN from_IN a_DT euthanized_JJ Wistar_NNP
          rat_NN (_( Charles_NNP River_NNP Laboratories_NNPS ,_, Wilmington_NNP ,_, MA_NNP ,_, USA_NNP )_) ,_,
          minced_JJ with_IN a_DT scalpel_NN ,_, and_CC digested_VBN for_IN 2_CD hours_NNS at_IN 37_CD °_NN C_NNP
          under_IN gentle_JJ agitation_NN with_IN 0_CD ._. 2_CD %_NN clostridial_NN collagenase_NN ._.
          Dermal_NNP cells_NNS were_VBD recovered_VBN by_IN centrifugation_NN of_IN the_DT
          digestion_NN mixture_NN at_IN 5000_CD rpm_NN in_IN a_DT table_NN top_JJ centrifuge_NN ,_,
          and_CC then_RB cultured_JJ in_IN 25_CD cm_NN 2_CD flasks_NNS in_IN DMEM_NNP with_IN 10_CD %_NN FBS_NNP
          and_CC 1_CD %_NN penicillin-streptomycin_JJ ._. Adherent_NNP cells_NNS were_VBD
          transduced_JJ with_IN an_DT amphotropic_JJ retrovirus_JJ ,_,
          DFG-hIL-_NNP 1_CD β-neo_JJ ,_, which_WDT encodes_NNS the_DT mature_VBP form_NN of_IN human_JJ
          IL-_NNP 1_CD β_NN fused_JJ to_TO the_DT leader_NN sequence_NN of_IN human_JJ parathyroid_NN
          hormone_NN to_TO enable_VB efficient_JJ secretion_NN ,_, and_CC neomycin_NN
          phosphotransferase_NN [_NN 21_CD ]_NN ._. Retroviral_NNP transductants_NNS were_VBD
          positively_RB selected_VBN in_IN complete_JJ DMEM_NNP containing_VBG Geneticin_NNP
          at_IN 0_CD ._. 5_CD mg_NN /_NN ml_NN ._. These_DT cells_NNS were_VBD found_VBN to_TO secrete_NN
          approximately_RB 250_CD ng_NN human_JJ IL-_NNP 1_CD β_NN /_NN ml_NN per_IN 10_CD 6_CD cells_NNS over_IN 24_CD
          hours_NNS ._.
        
        
          IL-_NNP 1_CD receptor_NN antagonist_NN and_CC IL-_NNP 1_CD β_NN treatment_NN
          Human_NNP IL-_NNP 1_CD Ra_NNP or_CC IL-_NNP 1_CD β_NN was_VBD delivered_VBN as_IN a_DT recombinant_JJ
          protein_NN or_CC by_IN expression_NN of_IN its_PRP$ cDNA_NN from_IN genetically_RB
          modified_VBN cells_NNS ._. For_IN the_DT addition_NN of_IN cells_NNS ,_, cultures_NNS of_IN
          HIG-_NNP 82_CD -_: IL-_NNP 1_CD Ra_NNP +_NN ,_, or_CC dermal_NN fibroblasts_NNS secreting_VBG IL-_NNP 1_CD β_NN ,_,
          were_VBD trypsinized_JJ ,_, washed_VBN in_IN PBS_NNP ,_, and_CC resuspended_JJ in_IN
          complete_JJ DMEM_NNP ._. The_DT cells_NNS were_VBD then_RB counted_VBN using_VBG a_DT
          hemocytometer_NN and_CC the_DT appropriate_JJ number_NN suspended_VBN in_IN 50_CD
          μl_NN DMEM_NNP for_IN subsequent_JJ addition_NN to_TO the_DT multiwell_NN HSF_NNP
          cultures_NNS ._.
        
        
          Biological_JJ assays_NNS
          PGE_NNP 
          2_CD ,_, IL-_NNP 1_CD β_NN ,_, and_CC IL-_NNP 1_CD Ra_NNP concentrations_NNS
          in_IN conditioned_VBN media_NNS were_VBD measured_VBN using_VBG ELISA_NNP according_VBG
          to_TO the_DT manufacturers_NNS '_POS instructions_NNS ._. These_DT assays_NNS do_VBP not_RB
          show_VB any_DT cross-reactivity_JJ with_IN other_JJ prostanoids_NNS ,_, or_CC
          rabbit_NN and_CC rat_NN forms_NNS of_IN IL-_NNP 1_CD or_CC IL-_NNP 1_CD Ra_NNP ._. Under_IN certain_JJ
          culture_NN conditions_NNS ,_, such_JJ as_IN those_DT described_VBN in_IN Figs_NNP 2_CD ,_, 3_CD ,_,
          4_CD ,_, 5_CD ,_, approximately_RB 1_CD /_NN 20_CD ,_, or_CC 50_CD μl_NN of_IN the_DT media_NNS volume_NN
          was_VBD removed_VBN periodically_RB and_CC replaced_VBN ,_, in_IN order_NN to_TO allow_VB
          analysis_NN at_IN strategic_JJ time_NN points_NNS without_IN significantly_RB
          altering_VBG the_DT evolving_VBG culture_NN conditions_NNS ._.
        
        
          Statistical_NNP analysis_NN
          All_DT results_NNS are_VBP presented_VBN as_IN means_VBZ ±_NN SD_NNP ._. Statistical_NNP
          analyses_NNS were_VBD performed_VBN using_VBG an_DT unpaired_JJ Student_NNP 's_POS 
          t_NN -_: test_NN ,_, and_CC 
          P_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN
          statistically_RB significant_JJ ._.
        
      
      
        Results_NNS
        To_TO quantitatively_RB compare_VB the_DT ability_NN of_IN recombinant_JJ
        (_( r_LS )_) IL-_NNP 1_CD Ra_NNP and_CC IL-_NNP 1_CD Ra_NNP provided_VBN by_IN genetically_RB modified_VBN cells_NNS
        (_( i_NNP ._. e_SYM ._. transgenic_JJ [_NN t_NN ]_NN IL-_NNP 1_CD Ra_NNP )_) to_TO inhibit_VB the_DT effects_NNS of_IN
        IL-_NNP 1_CD β_NN ,_, we_PRP performed_VBD a_DT series_NN of_IN experiments_NNS using_VBG both_DT
        static_JJ and_CC dynamic_JJ conditions_NNS of_IN IL-_NNP 1_CD stimulation_NN ._. Because_IN
        the_DT synovium_NN is_VBZ an_DT important_JJ contributor_NN to_TO pathogenesis_NNS in_IN
        arthritis_NN ,_, primary_JJ cultures_NNS of_IN HSFs_NNP were_VBD used_VBN as_IN target_NN
        cells_NNS ,_, and_CC concentrations_NNS of_IN PGE_NNP 
        2_CD in_IN media_NNS conditioned_VBN by_IN the_DT HSFs_NNP were_VBD
        used_VBN as_IN a_DT measure_NN of_IN IL-_NNP 1_CD β_NN stimulation_NN ._.
        In_IN our_PRP$ initial_JJ experiments_NNS we_PRP compared_VBD the_DT inhibitory_NN
        activity_NN of_IN rIL-_NN 1_CD Ra_NNP to_TO that_DT of_IN HIG-_NNP 82_CD -_: IL-_NNP 1_CD Ra_NNP +_NN cells_NNS -_: a_DT
        cell_NN line_NN engineered_VBN to_TO constitutively_RB express_VB human_JJ IL-_NNP 1_CD Ra_NNP
        -_: when_WRB each_DT was_VBD added_VBN to_TO HSF_NNP cultures_NNS simultaneously_RB with_IN
        IL-_NNP 1_CD β_NN ._. For_IN this_DT ,_, 5_CD ng_NN IL-_NNP 1_CD β_NN was_VBD added_VBN to_TO 5_CD ×_NN 10_CD 5_CD HSFs_NNP
        accompanied_VBN by_IN either_DT a_DT range_NN of_IN doses_NNS of_IN rIL-_NN 1_CD Ra_NNP or_CC
        increasing_VBG numbers_NNS of_IN HIG-_NNP 82_CD -_: IL-_NNP 1_CD Ra_NNP +_NN cells_NNS ._. Forty-eight_NNP
        hours_NNS later_RB ,_, the_DT conditioned_VBN media_NNS were_VBD analyzed_VBN for_IN IL-_NNP 1_CD Ra_NNP
        and_CC PGE_NNP 
        2_CD concentrations_NNS ._. A_DT plot_NN of_IN IL-_NNP 1_CD Ra_NNP
        concentration_NN versus_CC PGE_NNP 
        2_CD production_NN of_IN the_DT IL-_NNP 1_CD Ra_NNP treated_VBD
        cells_NNS ,_, relative_JJ to_TO PGE_NNP 
        2_CD levels_NNS of_IN control_NN HSFs_NNP incubated_JJ with_IN
        IL-_NNP 1_CD β_NN alone_RB ,_, is_VBZ shown_VBN in_IN Fig_NNP ._. 1_LS ._. Over_IN a_DT wide_JJ range_NN of_IN doses_NNS
        the_DT recombinant_JJ and_CC transgenic_JJ sources_NNS of_IN IL-_NNP 1_CD Ra_NNP were_VBD
        similarly_RB capable_JJ of_IN blocking_VBG the_DT effects_NNS of_IN the_DT added_VBN
        IL-_NNP 1_CD β_NN ._. For_IN each_DT source_NN of_IN IL-_NNP 1_CD Ra_NNP ,_, 50_CD %_NN IL-_NNP 1_CD β_NN inhibition_NN was_VBD
        extrapolated_VBN to_TO a_DT concentration_NN of_IN approximately_RB 230_CD ng_NN /_NN ml_NN
        IL-_NNP 1_CD Ra_NNP and_CC complete_JJ inhibition_NN at_IN approximately_RB 800_CD ng_NN /_NN ml_NN ._.
        This_DT translated_VBN to_TO IL-_NNP 1_CD Ra_NNP :_: IL-_NNP 1_CD β_NN ratios_NNS of_IN approximately_RB
        46_CD :_: 1_CD and_CC 160_CD :_: 1_CD ,_, respectively_RB ._. In_IN control_NN experiments_NNS ,_,
        levels_NNS of_IN PGE_NNP 
        2_CD produced_VBN by_IN IL-_NNP 1_CD β_NN challenge_NN of_IN
        co-culture_JJ of_IN HSFs_NNP with_IN nontransduced_JJ HIG-_NNP 82_CD cells_NNS were_VBD
        found_VBN to_TO be_VB identical_JJ to_TO those_DT of_IN HSFs_NNP alone_RB (_( data_NNS not_RB
        shown_VBN )_) ._.
        Relative_NNP to_TO the_DT end-point_JJ concentrations_NNS of_IN IL-_NNP 1_CD Ra_NNP ,_,
        there_EX was_VBD no_DT apparent_JJ difference_NN in_IN the_DT effectiveness_NN of_IN
        the_DT two_CD sources_NNS ._. By_IN adding_VBG the_DT recombinant_JJ protein_NN and_CC the_DT
        modified_VBN cells_NNS at_IN the_DT same_JJ time_NN as_IN IL-_NNP 1_CD β_NN ,_, the_DT concentration_NN
        of_IN rIL-_NN 1_CD Ra_NNP would_MD be_VB at_IN its_PRP$ maximum_NN at_IN the_DT time_NN of_IN initial_JJ
        IL-_NNP 1_CD β_NN stimulation_NN ._. That_DT of_IN the_DT tIL-_NN 1_CD Ra_NNP ,_, however_RB ,_, would_MD be_VB
        essentially_RB zero_CD ,_, and_CC would_MD not_RB reach_VB its_PRP$ maximal_NN
        concentration_NN until_IN 48_CD hours_NNS later_RB ,_, at_IN the_DT time_NN of_IN media_NNS
        harvest_VBP ._. Using_VBG this_DT rationale_NN ,_, we_PRP compared_VBD the_DT
        effectiveness_NN of_IN rIL-_NN 1_CD Ra_NNP and_CC tIL-_NN 1_CD Ra_NNP under_IN conditions_NNS in_IN
        which_WDT the_DT concentration_NN of_IN each_DT would_MD be_VB similar_JJ at_IN the_DT
        time_NN of_IN IL-_NNP 1_CD β_NN stimulation_NN ._. To_TO allow_VB sufficient_JJ time_NN for_IN the_DT
        IL-_NNP 1_CD Ra_NNP producing_VBG cells_NNS to_TO adhere_VB and_CC begin_VB transgenic_JJ
        expression_NN ,_, we_PRP performed_VBD experiments_NNS similar_JJ to_TO that_DT above_IN ,_,
        but_CC added_VBD the_DT IL-_NNP 1_CD β_NN 24_CD hours_NNS after_IN addition_NN of_IN the_DT range_NN of_IN
        doses_NNS of_IN rIL-_NN 1_CD Ra_NNP or_CC tIL-_NN 1_CD Ra_NNP producing_VBG cells_NNS to_TO the_DT HSF_NNP
        cultures_NNS ._. The_DT conditioned_VBN media_NNS were_VBD analyzed_VBN at_IN the_DT time_NN
        of_IN IL-_NNP 1_CD β_NN addition_NN and_CC 48_CD hours_NNS later_RB for_IN PGE_NNP 
        2_CD and_CC IL-_NNP 1_CD Ra_NNP content_NN ._. A_DT plot_NN of_IN the_DT
        IL-_NNP 1_CD Ra_NNP concentrations_NNS versus_CC PGE_NNP 
        2_CD production_NN relative_JJ to_TO IL-_NNP 1_CD β_NN
        stimulated_VBN controls_NNS is_VBZ shown_VBN in_IN Fig_NNP ._. 2_LS ._. To_TO illustrate_VB the_DT
        change_NN in_IN IL-_NNP 1_CD Ra_NNP concentration_NN over_IN time_NN in_IN the_DT wells_NNS
        receiving_VBG the_DT IL-_NNP 1_CD Ra_NNP producing_VBG cells_NNS ,_, we_PRP plotted_VBD the_DT final_JJ
        PGE_NNP 
        2_CD concentration_NN versus_CC the_DT IL-_NNP 1_CD Ra_NNP
        concentration_NN at_IN the_DT time_NN of_IN IL-_NNP 1_CD β_NN stimulation_NN and_CC at_IN the_DT
        end_NN of_IN the_DT 48_CD hour_NN incubation_NN ._. Because_IN these_DT values_NNS
        represent_VBP the_DT starting_VBG and_CC end-point_JJ IL-_NNP 1_CD Ra_NNP concentrations_NNS ,_,
        the_DT effective_JJ tIL-_NN 1_CD Ra_NNP dose_NN should_MD lie_VB somewhere_RB between_IN and_CC
        is_VBZ represented_VBN by_IN the_DT shaded_JJ area_NN between_IN the_DT two_CD
        curves_NNS ._.
        As_IN might_MD be_VB expected_VBN of_IN a_DT competitive_JJ inhibitor_NN ,_,
        preincubation_NN of_IN the_DT HSF_NNP with_IN IL-_NNP 1_CD Ra_NNP for_IN 24_CD hours_NNS before_IN
        IL-_NNP 1_CD β_NN stimulation_NN significantly_RB reduced_VBD the_DT 50_CD %_NN inhibition_NN
        level_NN for_IN each_DT source_NN of_IN IL-_NNP 1_CD Ra_NNP ._. For_IN the_DT recombinant_JJ
        protein_NN ,_, 50_CD %_NN IL-_NNP 1_CD β_NN inhibition_NN was_VBD extrapolated_VBN to_TO 50_CD ng_NN /_NN ml_NN
        IL-_NNP 1_CD Ra_NNP ,_, and_CC for_IN the_DT tIL-_NN 1_CD Ra_NNP 50_CD %_NN inhibition_NN fell_VBD between_IN 10_CD
        and_CC 50_CD ng_NN /_NN ml_NN ._. For_IN complete_JJ inhibition_NN approximately_RB 950_CD
        ng_NN /_NN ml_NN rIL-Ra_JJ was_VBD required_VBN ,_, whereas_IN for_IN the_DT tIL-_NN 1_CD Ra_NNP between_IN
        400_CD and_CC 700_CD ng_NN /_NN ml_NN was_VBD necessary_JJ ._.
        The_DT previous_JJ experiments_NNS provided_VBD evidence_NN that_IN the_DT two_CD
        molecules_NNS rIL-_NN 1_CD Ra_NNP and_CC tIL-_NN 1_CD Ra_NNP were_VBD functionally_RB similar_JJ and_CC
        equally_RB capable_JJ of_IN blocking_VBG the_DT effects_NNS of_IN IL-_NNP 1_CD β_NN ._. They_PRP also_RB
        suggested_VBD that_DT time_NN was_VBD a_DT factor_NN critical_JJ to_TO comparing_VBG the_DT
        effectiveness_NN of_IN rIL-_NN 1_CD Ra_NNP and_CC IL-_NNP 1_CD Ra_NNP constitutively_RB produced_VBN
        by_IN genetically_RB modified_VBN cells_NNS ._. Thus_RB ,_, in_IN several_JJ additional_JJ
        experiments_NNS we_PRP monitored_VBD the_DT relationship_NN between_IN IL-_NNP 1_CD Ra_NNP
        and_CC IL-_NNP 1_CD β_NN stimulation_NN daily_JJ over_IN a_DT 96_CD hour_NN interval_NN ._. For_IN
        these_DT experiments_NNS ,_, three_CD doses_NNS of_IN rIL-_NN 1_CD Ra_NNP or_CC HIG-_NNP 82_CD -_: IL-_NNP 1_CD Ra_NNP
        +_NN cells_NNS were_VBD used_VBN ,_, which_WDT from_IN Fig_NNP ._. 2_LS provided_VBN either_CC low_JJ
        (_( approximately_RB 10_CD -_: 15_CD %_NN )_) ,_, medium_NN (_( approximately_RB 25_CD -_: 50_CD %_NN )_) ,_, or_CC
        high_JJ level_NN (_( approximately_RB 70_CD -_: 80_CD %_NN )_) inhibition_NN of_IN IL-_NNP 1_CD β_NN ._. HSFs_NNP
        were_VBD cultured_JJ in_IN the_DT presence_NN of_IN the_DT various_JJ doses_NNS of_IN cells_NNS
        or_CC protein_NN ,_, followed_VBD 24_CD hours_NNS later_RB by_IN the_DT addition_NN of_IN 5_CD ng_NN
        IL-_NNP 1_CD β_NN ._. At_IN 24_CD hour_NN intervals_NNS ,_, IL-_NNP 1_CD Ra_NNP and_CC PGE_NNP 
        2_CD were_VBD measured_VBN in_IN the_DT conditioned_VBN
        media_NNS ._. As_IN shown_VBN in_IN Fig_NNP ._. 3_LS ,_, under_IN these_DT static_JJ culture_NN
        conditions_NNS there_RB was_VBD little_RB meaningful_JJ change_NN in_IN the_DT levels_NNS
        of_IN PGE_NNP 
        2_CD production_NN over_IN time_NN ._. At_IN the_DT low_NN and_CC
        medium_NN doses_NNS rIL-_NN 1_CD Ra_NNP had_VBD little_RB protective_JJ effect_NN but_CC ,_,
        relative_JJ to_TO the_DT 24_CD hour_NN time_NN point_NN ,_, a_DT significant_JJ increase_NN
        in_IN IL-_NNP 1_CD stimulation_NN was_VBD seen_VBN in_IN the_DT wells_NNS receiving_VBG the_DT
        high_JJ dose_NN by_IN day_NN 4_CD ._. In_IN the_DT wells_NNS receiving_VBG the_DT
        HIG-_NNP 82_CD -_: IL-_NNP 1_CD Ra_NNP +_NN cells_NNS ,_, protection_NN from_IN IL-_NNP 1_CD stimulation_NN was_VBD
        maintained_VBN over_IN time_NN ._. Although_IN the_DT mean_NN levels_NNS of_IN PGE_NNP 
        2_CD were_VBD reduced_VBN over_IN the_DT 4_CD days_NNS of_IN the_DT
        experiment_NN ,_, this_DT was_VBD not_RB statistically_RB significant_JJ ._. Thus_RB ,_,
        under_IN these_DT conditions_NNS there_EX were_VBD no_DT dramatic_JJ differences_NNS
        between_IN a_DT single_JJ dose_NN of_IN rIL-_NN 1_CD Ra_NNP and_CC the_DT tIL-_NN 1_CD Ra_NNP producing_VBG
        cells_NNS ._.
        It_PRP has_VBZ been_VBN shown_VBN 
        in_IN vivo_NN that_IN agents_NNS injected_VBN into_IN the_DT
        joint_JJ space_NN can_MD be_VB cleared_VBN from_IN the_DT synovial_NN fluid_JJ in_IN as_RB
        little_JJ as_IN 30_CD min_NN ,_, suggesting_VBG a_DT steady_JJ egress_NNS of_IN solutes_NNS
        from_IN the_DT joint_NN ._. Thus_RB ,_, to_TO compare_VB the_DT effects_NNS of_IN rIL-_NN 1_CD Ra_NNP and_CC
        tIL-_NN 1_CD Ra_NNP producing_VBG cells_NNS under_IN more_RBR dynamic_JJ conditions_NNS ,_,
        perhaps_RB closer_JJR to_TO those_DT that_WDT might_MD be_VB encountered_VBN in_IN the_DT
        joint_NN 
        in_IN vivo_NN ,_, experiments_NNS were_VBD performed_VBN
        identically_RB to_TO that_DT described_VBD for_IN Fig_NNP 3_CD except_IN that_DT one_CD half_NN
        of_IN the_DT culture_NN media_NNS was_VBD replaced_VBN every_DT 24_CD hours_NNS for_IN 4_CD
        days_NNS ._. Analysis_NNP of_IN media_NNS recovered_VBD at_IN each_DT day_NN showed_VBD that_IN
        the_DT medium_NN and_CC low_JJ doses_NNS of_IN rIL-_NN 1_CD Ra_NNP provided_VBD a_DT marginal_JJ
        level_NN of_IN protection_NN over_IN time_NN ,_, and_CC in_IN wells_NNS receiving_VBG the_DT
        highest_JJS dose_NN initially_RB high_JJ levels_NNS of_IN protection_NN were_VBD
        steadily_RB lost_VBN (_( Fig_NNP 4_LS )_) ._. In_IN stark_JJ contrast_NN ,_, the_DT HSFs_NNP
        incubated_JJ with_IN the_DT IL-_NNP 1_CD Ra_NNP producing_VBG cells_NNS exhibited_VBN a_DT sharp_JJ
        reduction_NN in_IN PGE_NNP 
        2_CD production_NN throughout_IN the_DT course_NN of_IN
        the_DT experiment_NN ._. For_IN these_DT groups_NNS ,_, HSF_NNP cultures_NNS receiving_VBG
        even_RB the_DT lowest_JJS dose_NN of_IN HIG-_NNP 82_CD -_: IL-_NNP 1_CD Ra_NNP +_NN cells_NNS showed_VBD
        approximately_RB 70_CD %_NN inhibition_NN of_IN IL-_NNP 1_CD β_NN at_IN 96_CD hours_NNS ._.
        The_DT previous_JJ experiment_NN was_VBD intended_VBN to_TO evaluate_VB the_DT
        effects_NNS of_IN IL-_NNP 1_CD Ra_NNP under_IN dynamic_JJ conditions_NNS following_VBG a_DT
        single_JJ stimulus_NN of_IN IL-_NNP 1_CD β_NN ._. To_TO establish_VB a_DT situation_NN of_IN
        chronic_JJ IL-_NNP 1_CD β_NN stimulation_NN as_IN might_MD be_VB encountered_VBN in_IN an_DT
        arthritic_JJ joint_NN ,_, experiments_NNS were_VBD designed_VBN like_IN that_DT
        described_VBD for_IN Figure_NN 4_CD ,_, but_CC in_IN this_DT case_NN the_DT source_NN of_IN
        IL-_NNP 1_CD β_NN was_VBD provided_VBN by_IN the_DT addition_NN of_IN dermal_NN fibroblasts_NNS
        genetically_RB modified_VBN to_TO constitutively_RB secrete_NN mature_VBP human_JJ
        IL-_NNP 1_CD β_NN ._. As_IN shown_VBN in_IN Fig_NNP ._. 5_LS ,_, using_VBG these_DT conditions_NNS the_DT
        single_JJ dose_NN of_IN rIL-_NN 1_CD Ra_NNP was_VBD unable_JJ to_TO block_VB the_DT effects_NNS of_IN
        persistent_JJ IL-_NNP 1_CD β_NN production_NN ._. Even_RB at_IN the_DT highest_JJS dose_NN ,_, the_DT
        steady_JJ dilution_NN of_IN rIL-_NN 1_CD Ra_NNP in_IN the_DT presence_NN of_IN constant_JJ
        IL-_NNP 1_CD β_NN synthesis_NN rapidly_RB lost_VBD its_PRP$ protective_JJ effects_NNS ._. In_IN
        this_DT milieu_NN ,_, however_RB ,_, the_DT potency_NN of_IN gene_NN transfer_NN as_IN a_DT
        method_NN of_IN drug_NN delivery_NN was_VBD perhaps_RB most_RBS effectively_RB
        illustrated_VBN ._. The_DT maintenance_NN of_IN and_CC gradual_JJ increase_NN in_IN
        IL-_NNP 1_CD Ra_NNP concentration_NN provided_VBN by_IN ongoing_JJ synthesis_NN by_IN the_DT
        genetically_RB modified_VBN cells_NNS at_IN all_DT doses_NNS provided_VBN sustained_VBN
        and_CC increased_VBN protection_NN from_IN chronic_JJ synthesis_NN of_IN IL-_NNP 1_CD β_NN
        over_IN time_NN ._.
      
      
        Discussion_NNP
        For_IN the_DT treatment_NN of_IN arthritis_NN ,_, gene_NN therapy_NN has_VBZ the_DT
        theoretical_JJ advantage_NN over_IN protein_NN therapy_NN of_IN sustained_VBN
        delivery_NN of_IN the_DT therapeutic_JJ product_NN to_TO a_DT discrete_JJ site_NN ._.
        Although_IN its_PRP$ feasibility_NN and_CC effectiveness_NN in_IN animal_NN models_NNS
        are_VBP now_RB well_RB established_VBN [_NN 13_CD 14_CD 16_CD 17_CD 18_CD 19_CD 23_CD 24_CD 25_CD ]_NN ,_,
        no_DT direct_JJ study_NN of_IN the_DT intrinsic_JJ merits_NNS of_IN using_VBG
        genetically_RB modified_VBN cells_NNS as_IN a_DT mechanism_NN for_IN protein_NN
        delivery_NN has_VBZ been_VBN reported_VBN ._. We_PRP postulated_JJ several_JJ potential_JJ
        benefits_NNS that_WDT could_MD arise_VB ,_, including_VBG natural_JJ protein_NN
        processing_NN and_CC intercellular_NN presentation_NN of_IN the_DT transgene_NN
        product_NN ._. Indeed_RB ,_, it_PRP is_VBZ known_VBN that_DT anakinra_NN ,_, the_DT recombinant_JJ
        form_NN of_IN human_JJ IL-_NNP 1_CD Ra_NNP ,_, differs_VBZ from_IN its_PRP$ naturally_RB occurring_VBG
        counterpart_NN by_IN possessing_VBG an_DT additional_JJ amino-terminal_JJ
        methionine_NN residue_NN and_CC lacking_VBG glycosylation_NN [_NN 26_CD ]_NN ._. In_IN
        the_DT first_JJ part_NN of_IN the_DT present_JJ study_NN similar_JJ end-point_JJ
        levels_NNS of_IN transgenic_JJ and_CC recombinant_JJ IL-_NNP 1_CD Ra_NNP were_VBD necessary_JJ
        to_TO inhibit_VB fully_RB the_DT response_NN of_IN synoviocytes_NNS to_TO a_DT single_JJ
        challenge_NN with_IN IL-_NNP 1_CD β_NN ._. Furthermore_RB ,_, and_CC in_IN agreement_NN with_IN
        earlier_JJR literature_NN on_IN this_DT subject_JJ [_NN 4_CD 5_CD 27_CD ]_NN ,_, both_DT forms_NNS
        of_IN IL-_NNP 1_CD Ra_NNP required_VBD a_DT molar_NN excess_JJ over_IN IL-_NNP 1_CD of_IN at_IN least_JJS two_CD
        orders_NNS of_IN magnitude_NN to_TO exercise_VB an_DT inhibition_NN of_IN 100_CD %_NN ._.
        Altogether_RB ,_, these_DT data_NNS suggest_VBP that_IN the_DT biochemical_JJ
        alterations_NNS of_IN the_DT recombinant_JJ IL-_NNP 1_CD Ra_NNP do_VBP not_RB significantly_RB
        affect_VB its_PRP$ ability_NN to_TO antagonize_VB the_DT responses_NNS of_IN synovial_NN
        fibroblasts_NNS to_TO human_JJ IL-_NNP 1_CD β_NN ._.
        From_IN the_DT data_NNS presented_VBN in_IN Fig_NNP ._. 2_LS ,_, however_RB ,_, a_DT modest_JJ
        increase_NN in_IN the_DT effectiveness_NN of_IN tIL-_NN 1_CD Ra_NNP is_VBZ suggested_VBN when_WRB
        one_CD considers_VBZ the_DT relative_JJ concentrations_NNS of_IN recombinant_JJ
        and_CC transgenic_JJ IL-_NNP 1_CD Ra_NNP with_IN time_NN ._. In_IN experiments_NNS in_IN which_WDT
        IL-_NNP 1_CD β_NN was_VBD added_VBN at_IN the_DT same_JJ time_NN as_IN the_DT source_NN of_IN IL-_NNP 1_CD Ra_NNP ,_,
        similar_JJ end-point_JJ concentrations_NNS of_IN IL-_NNP 1_CD Ra_NNP were_VBD found_VBN to_TO
        provide_VB corresponding_JJ inhibitory_NN effects_NNS ,_, despite_IN the_DT fact_NN
        that_IN the_DT recombinant_JJ protein_NN was_VBD at_IN its_PRP$ maximal_NN
        concentration_NN at_IN the_DT time_NN of_IN IL-_NNP 1_CD stimulation_NN whereas_IN that_DT
        from_IN the_DT modified_VBN cells_NNS was_VBD zero_CD ._. In_IN other_JJ experiments_NNS in_IN
        which_WDT ,_, prior_RB to_TO IL-_NNP 1_CD stimulation_NN ,_, time_NN was_VBD allowed_VBN for_IN the_DT
        IL-_NNP 1_CD Ra_NNP producing_VBG cells_NNS to_TO establish_VB concentrations_NNS
        equivalent_JJ to_TO that_DT of_IN the_DT recombinant_JJ ,_, the_DT inhibitory_NN curve_NN
        was_VBD shifted_VBN slightly_RB to_TO the_DT left_NN ,_, indicating_VBG a_DT slight_JJ
        increase_NN in_IN the_DT effectiveness_NN of_IN IL-_NNP 1_CD Ra_NNP when_WRB provided_VBN as_IN a_DT
        transgene_NN product_NN ._. This_DT may_MD arise_VB from_IN increased_VBN
        concentrations_NNS of_IN the_DT IL-_NNP 1_CD Ra_NNP gene_NN product_NN in_IN the_DT cellular_JJ
        microenvironment_NN where_WRB the_DT protein_NN is_VBZ locally_RB synthesized_JJ
        and_CC secreted_JJ ._.
        Interestingly_RB ,_, following_VBG extended_VBN culture_NN under_IN static_JJ
        conditions_NNS ,_, largely_RB unremarkable_JJ differences_NNS in_IN activity_NN
        were_VBD observed_VBN between_IN the_DT constitutively_RB produced_VBN tIL-_NN 1_CD Ra_NNP
        and_CC rIL-_NN 1_CD Ra_NNP ._. Significant_JJ differences_NNS between_IN the_DT two_CD
        methods_NNS of_IN protein_NN delivery_NN were_VBD only_RB found_VBN under_IN dynamic_JJ
        conditions_NNS in_IN which_WDT the_DT concentration_NN of_IN rIL-_NN 1_CD Ra_NNP was_VBD
        reduced_VBN with_IN time_NN ._. In_IN these_DT situations_NNS ,_, such_JJ as_IN that_DT
        reported_VBD in_IN Figs_NNP 4_CD and_CC 5_CD ,_, the_DT importance_NN of_IN maintaining_VBG the_DT
        local_JJ level_NN of_IN IL-_NNP 1_CD Ra_NNP became_VBD dramatically_RB apparent_JJ ,_, as_IN were_VBD
        the_DT advantages_NNS of_IN gene_NN transfer_NN as_IN a_DT means_NN of_IN protein_NN
        delivery_NN ._. In_IN the_DT face_NN of_IN continual_JJ dilution_NN ,_, the_DT
        constitutive_JJ production_NN of_IN the_DT IL-_NNP 1_CD Ra_NNP gene_NN product_NN was_VBD able_JJ
        to_TO maintain_VB effective_JJ protein_NN levels_NNS and_CC was_VBD able_JJ to_TO
        sustain_VB and_CC increase_VB protection_NN of_IN the_DT HSFs_NNP from_IN IL-_NNP 1_CD
        stimulation_NN as_IN time_NN progressed_VBD ._. This_DT was_VBD even_RB more_RBR
        pronounced_JJ under_IN conditions_NNS of_IN continuing_VBG IL-_NNP 1_CD production_NN ,_,
        in_IN which_WDT the_DT rIL-_NN 1_CD Ra_NNP was_VBD readily_RB overwhelmed_VBN ._. It_PRP should_MD be_VB
        noted_VBN that_IN all_DT of_IN the_DT experiments_NNS performed_VBN in_IN this_DT study_NN
        used_VBD HSFs_NNP derived_VBD from_IN OA_NNP patients_NNS ._. It_PRP remains_VBZ possible_JJ
        that_IN the_DT amplitude_NN of_IN the_DT responses_NNS to_TO IL-_NNP 1_CD and_CC IL-_NNP 1_CD Ra_NNP may_MD
        vary_VB somewhat_RB between_IN HSFs_NNP from_IN OA_NNP ,_, RA_NNP ,_, and_CC nondiseased_JJ
        individuals_NNS ;_: however_RB ,_, the_DT overall_JJ result_NN will_MD probably_RB
        remain_VB the_DT same_JJ ._.
        In_IN rodent_NN models_NNS of_IN RA_NNP ,_, maximum_JJ therapeutic_JJ effects_NNS are_VBP
        only_RB achieved_VBN when_WRB pumps_NNS are_VBP used_VBN to_TO maintain_VB a_DT constant_JJ
        supply_NN of_IN large_JJ amounts_NNS of_IN recombinant_JJ IL-_NNP 1_CD Ra_NNP ._. Under_IN these_DT
        conditions_NNS IL-_NNP 1_CD Ra_NNP has_VBZ both_DT antierosive_JJ and_CC
        anti-inflammatory_JJ effects_NNS in_IN collagen-induced_JJ arthritis_NN ._. As_IN
        discussed_VBN by_IN Bendele_NNP and_CC coworkers_NNS [_NN 3_CD ]_NN ,_, constant_JJ serum_NN
        concentrations_NNS of_IN approximately_RB 1_CD μg_NN IL-_NNP 1_CD Ra_NNP /_NN ml_NN are_VBP
        antierosive_JJ ,_, but_CC it_PRP is_VBZ necessary_JJ to_TO achieve_VB serum_NN
        concentrations_NNS of_IN approximately_RB 5_CD μg_NN IL-_NNP 1_CD Ra_NNP /_NN ml_NN before_IN
        important_JJ anti-inflammatory_JJ effects_NNS are_VBP seen_VBN ._. A_DT single_JJ ,_,
        subcutaneous_JJ injection_NN of_IN 150_CD mg_NN recombinant_JJ IL-_NNP 1_CD Ra_NNP in_IN
        humans_NNS achieves_VBZ a_DT peak_NN plasma_NN concentration_NN of_IN only_RB about_IN
        1_CD ._. 6_CD μg_NN IL-_NNP 1_CD Ra_NNP /_NN ml_NN ,_, and_CC concentrations_NNS superior_JJ or_CC equal_JJ to_TO 1_CD
        μg_NN IL-_NNP 1_CD Ra_NNP /_NN ml_NN exist_VB only_RB for_IN about_IN 14_CD hours_NNS ._. Local_JJ ,_,
        intra-articular_JJ gene_NN delivery_NN of_IN IL-_NNP 1_CD Ra_NNP could_MD produce_VB
        enough_JJ protein_NN ,_, with_IN only_RB a_DT single_JJ injection_NN of_IN vector_NN ,_, to_TO
        trigger_VB both_DT antierosive_JJ and_CC anti-inflammatory_JJ local_JJ
        effects_NNS ._. This_DT is_VBZ of_IN real_JJ interest_NN because_IN the_DT clinical_JJ
        response_NN to_TO Kineret_NNP is_VBZ modest_JJ and_CC might_MD be_VB explained_VBN by_IN
        these_DT circumstances_NNS ._. Moreover_RB ,_, its_PRP$ antierosive_JJ effect_NN is_VBZ
        more_RBR pronounced_JJ than_IN the_DT anti-inflammatory_JJ one_CD probably_RB
        because_IN of_IN the_DT low_JJ local_JJ concentrations_NNS ._.
        As_IN suggested_VBN by_IN our_PRP$ results_NNS ,_, maintaining_VBG higher_JJR 
        in_IN vivo_NN concentrations_NNS of_IN IL-_NNP 1_CD Ra_NNP in_IN a_DT
        sustained_VBN manner_NN may_MD be_VB key_JJ to_TO realizing_VBG the_DT full_JJ
        therapeutic_JJ potential_NN of_IN this_DT material_NN ._. Gene_NNP delivery_NN may_MD
        offer_VB the_DT greatest_JJS chance_NN of_IN early_JJ success_NN ._. Recent_JJ data_NNS
        from_IN our_PRP$ laboratory_NN have_VBP shown_VBN that_IN the_DT synovial_NN lining_NN is_VBZ
        capable_JJ of_IN maintaining_VBG therapeutic_JJ levels_NNS of_IN transgene_NN
        expression_NN for_IN at_IN least_JJS 6_CD months_NNS [_NN 28_CD ]_NN ,_, providing_VBG
        increased_VBN optimism_NN for_IN the_DT use_NN of_IN gene_NN transfer_NN in_IN the_DT
        treatment_NN of_IN chronic_JJ articular_NN disease_NN ._. Indeed_RB ,_, IL-_NNP 1_CD Ra_NNP gene_NN
        therapy_NN has_VBZ demonstrated_VBN impressive_JJ efficacy_NN in_IN animal_NN
        models_NNS of_IN RA_NNP and_CC OA_NNP ,_, and_CC a_DT phase_NN I_PRP human_JJ trial_NN has_VBZ recently_RB
        confirmed_VBN that_IN the_DT human_JJ IL-_NNP 1_CD Ra_NNP cDNA_NN can_MD be_VB safely_RB
        transferred_VBN to_TO and_CC expressed_VBD within_IN human_JJ rheumatoid_NN joints_NNS
        [_NN 19_CD ]_NN ._. A_DT planned_VBN phase_NN II_NNP study_NN will_MD determine_VB the_DT
        efficacy_NN of_IN this_DT procedure_NN ._.
      
      
        Conclusion_NNP
        Recombinant_NNP human_JJ IL-_NNP 1_CD Ra_NNP and_CC human_JJ IL-_NNP 1_CD Ra_NNP synthesized_JJ
        transgenically_RB in_IN mammalian_JJ cells_NNS are_VBP equipotent_NN
        antagonists_NNS of_IN human_JJ IL-_NNP 1_CD β_NN ._. Our_PRP$ data_NNS indicate_VBP that_IN the_DT
        greater_JJR efficiency_NN noted_VBD for_IN transgenic_JJ IL-_NNP 1_CD Ra_NNP in_IN previous_JJ
        animal_NN gene_NN therapy_NN investigations_NNS reflects_VBZ the_DT ability_NN of_IN
        gene_NN delivery_NN to_TO maintain_VB higher_JJR 
        in_IN vivo_NN concentrations_NNS of_IN IL-_NNP 1_CD Ra_NNP in_IN a_DT
        sustained_VBN manner_NN ._. This_DT property_NN was_VBD particularly_RB striking_JJ
        under_IN experimental_JJ conditions_NNS that_WDT resemble_VBP those_DT found_VBD
        during_IN chronic_JJ inflammatory_JJ conditions_NNS ,_, in_IN which_WDT IL-_NNP 1_CD β_NN is_VBZ
        produced_VBN continually_RB and_CC the_DT concentration_NN of_IN rIL-_NN 1_CD Ra_NNP
        administered_VBN as_IN a_DT single_JJ bolus_JJ progressively_RB falls_NNS ._. These_DT
        findings_NNS are_VBP relevant_JJ to_TO the_DT clinical_JJ use_NN of_IN Kineret_NNP and_CC
        the_DT possible_JJ future_JJ use_NN of_IN IL-_NNP 1_CD Ra_NNP gene_NN therapy_NN to_TO treat_VB
        joint_JJ diseases_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        DMEM_NNP =_SYM Dulbecco_NNP 's_POS modified_VBN Eagle_NNP medium_NN ;_: ELISA_NNP =_SYM
        enzyme-linked_JJ immunosorbent_NN assay_NN ;_: FBS_NNP =_SYM fetal_JJ bovine_JJ
        serum_NN ;_: HSF_NNP =_SYM human_JJ synovial_NN fibroblast_NN ;_: (_( r_LS /_NN t_NN )_) IL-_NNP 1_CD Ra_NNP =_SYM
        (_( recombinant_JJ /_NN transgenic_JJ )_) IL-_NNP 1_CD receptor_NN antagonist_NN ;_: OA_NNP =_SYM
        osteoarthritis_NNS ;_: PBS_NNP =_SYM phosphate-buffered_JJ saline_NN ;_: PGE_NNP 
        2_CD =_SYM prostaglandin_NN E_NNP 
        2_CD ;_: RA_NNP =_SYM rheumatoid_NN arthritis_NN ._.
      
    
  
